The first industrial batch of our vaccine has been produced

After years of studies con­firm­ing the safety and tol­er­ance of this com­pound in lab­o­ra­tory animals and dogs with chronic pain, Xeptiva now has its first GMP-quality vaccine, meaning it meets a series of inter­na­tional man­u­fac­tur­ing stan­dards that ensure its safety.

Reach­ing this mile­stone is a sig­nif­i­cant achieve­ment for Xeptiva, as it means our immu­niza­tion meets a rig­or­ous series of inter­na­tional stan­dards that guar­an­tee its safety and quality.

This is a fun­da­men­tal step toward the clin­i­cal appli­ca­tion of this promis­ing ther­a­peu­tic solu­tion, bring­ing us closer to pro­vid­ing com­pan­ion animals an effec­tive and safe alter­na­tive for chronic pain that sig­nif­i­cantly improves their quality of life.

The indus­trial pro­duc­tion of this first GMP-quality vaccine would not have been pos­si­ble without sig­nif­i­cant invest­ment in eco­nomic and human resources. Biotech devel­op­ment requires long-term com­mit­ment. For over 10 years, we have allo­cated funds for basic research, acqui­si­tion of new tech­nolo­gies and ongoing train­ing for our team at all levels.

It is crucial to high­light the col­lab­o­ra­tion with aca­demic insti­tu­tions such as the Insti­tut Pasteur de Mon­te­v­ideo and indus­trial part­ners like ATGEN and Merck Argentina, as they have been fun­da­men­tal in advanc­ing our projects.

Our vaccine to treat dogs with chronic pain is the result of over a decade of research that began at the Neu­rode­gen­er­a­tion Lab­o­ra­tory of the Insti­tut Pasteur de Mon­te­v­ideo and led to the cre­ation of Xeptiva.

Our sci­en­tific team has focused for years on thor­oughly under­stand­ing the bio­log­i­cal and phys­i­o­log­i­cal mech­a­nisms under­ly­ing chronic inflam­ma­tion and pain, with the goal of devel­op­ing inno­va­tive ther­a­peu­tic strate­gies to neu­tral­ize these pro­cesses.

In 2021, our team of researchers decided to take a step further and create Xeptiva Ther­a­peu­tics to develop ther­a­pies for pain in com­pan­ion animals. This led to the first pro­to­type of the vaccine, made from syn­thet­i­cally designed pro­teins that have the capac­ity to neu­tral­ize the mech­a­nisms that cause chronic inflam­ma­tion and pain in animals.